A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
一项针对 HER2/neu 阳性转移性乳腺癌患者的一线化疗联合曲妥珠单抗(有或无贝伐珠单抗)的随机 III 期双盲安慰剂对照试验:ECOG-ACRIN 癌症研究组 (E1105) 的一项试验
期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-024-07417-4
Mezzanotte-Sharpe, Jessica; ONeill, Anne; Mayer, Ingrid A; Arteaga, Carlos L; Yang, Ximing J; Wagner, Lynne I; Cella, David; Meropol, Neal J; Alpaugh, R Katherine; Saphner, Thomas J; Swaney, Robert E; Hoelzer, Karen L; Gradishar, William J; Abramson, Vandana G; Sundaram, P Kothai; Jilani, Shamim Z; Perez, Edith A; Lin, Nancy U; Jahanzeb, Mohammad; Wolff, Antonio C; Sledge, George W; Reid, Sonya A